Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Grabar, S.    Weiss, L.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

Sophie Grabar, MD, MPH; Vincent Le Moing, MD, MPH; Cécile Goujard, MD; Catherine Leport, MD, PhD; Michel D. Kazatchkine, MD, PhD; Dominique Costagliola, PhD; and Laurence Weiss, MD, PhD

19 September 2000 | Volume 133 Issue 6 | Pages 401-410

Background: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not known.

Objective: To study the relation between clinical outcome of HIV-infected patients receiving highly active antiretroviral therapy (HAART) and early immunologic and virologic responses to such therapy.

Design: Prospective cohort study.

Setting: 68 hospitals in France.

Patients: 2236 protease inhibitor–naive patients.

Intervention: Initiation of HAART with one protease inhibitor and two nucleoside analogues between July 1996 and March 1997.

Measurements: Immunologic and virologic response at 6 months. Multivariate Cox models were used to assess the relation between these responses and progression to a new AIDS-defining event or death.

Results: On the basis of 6-month immunologic and virologic responses, patients were classified into four groups: complete response (47.5%), complete nonresponse (16.2%), immunologic response only (19.0%), and virologic response only (17.3%). After month 6 and within a median of 18 months, 69 patients died and 123 experienced a new AIDS-defining event. After adjustment, complete nonresponders and those with only a virologic response had significantly higher risks for clinical progression at 6 months (relative risk, 3.38 [95% CI, 2.28 to 5.02] and 1.98 [CI, 1.26 to 3.10], respectively) than complete responders. The difference between complete responders and those with only an immunologic response at 6 months was weaker and nonsignificant (relative risk, 1.55 [CI, 0.96 to 2.50]).

Conclusions: Immunologic response after 6 months of HAART indicates a favorable clinical outcome in HIV-infected patients regardless of virologic response. This suggests that both immunologic and virologic markers should be used in clinical practice to evaluate treatment response.

Author and Article Information

From Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bichat Claude Bernard, and Hôpital Broussais, Paris, France; and Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

For the Clinical Epidemiology Group of the French Hospital Database on HIV, see Appendix.

Acknowledgments: The authors thank all participants of the French Hospital Database on HIV and especially the research assistants, without whom this work would not have been possible.

Grant Support: The French Hospital Database on HIV is supported by the Agence Nationale de Recherches sur le SIDA (ANRS), the Fondation pour la Recherche Médicale (SIDACTION), INSERM, and the French Ministry of Health.

Requests for Single Reprints: Sophie Grabar, MD, MPH, INSERM SC4, Faculté de Médecine St. Antoine, 27 rue Chaligny, 75571 Paris Cedex 12, France.

Current Author Addresses: Drs. Grabar and Costagliola: INSERM SC4, Faculté de Médecine St. Antoine, 27 rue Chaligny, 75571 Paris Cedex 12, France.

Drs. Le Moing and Leport: Hôpital Bichat Claude Bernard, Service de Maladies Infectieuses et Tropicales, 46 rue Huchard, 75877 Paris Cedex 18, France.

Dr. Goujard: Hôpital Bicêtre, Service de Médecine Interne, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France.

Drs. Kazatchkine and Weiss: Hôpital Service d'Immunologie Clinique, Européen Georges Pompidon, 20 rue Leblanc, 75908 Paris Cedex 15, France.

Author Contributions: Conception and design: S. Grabar, D. Costagliola, L. Weiss.

Analysis and interpretation of the data: S. Grabar, V. Le Moing, C. Goujard, D. Costagliola, L. Weiss.

Drafting of the article: S. Grabar, V. Le Moing, C. Goujard, M.D. Kazatchkine, L. Weiss.

Critical revision of the article for important intellectual content: S. Grabar, V. Le Moing, C. Goujard, C. Leport, M.D. Kazatchkine, D. Costagliola, L. Weiss.

Final approval of the article: S. Grabar, V. Le Moing, C. Goujard, C. Leport, M.D. Kazatchkine, D. Costagliola, L. Weiss.

Statistical expertise: D. Costagliola.

Related articles in Annals:

Editorials
Assessing the Benefits of Antiretroviral Therapy
Roy M. Gulick

Annals 2000 133: 471-473. [Full Text]  

Summaries for Patients
Cell Count, Viral Load, and Clinical Outcome in Patients with HIV Infection after Highly Active Antiretroviral Therapy

Annals 2000 133: I-16. [Full Text]  

This article has been cited by other articles:

				M.-L. Dion, R. Bordi, J. Zeidan, R. Asaad, M.-R. Boulassel, J.-P. Routy, M. M. Lederman, R.-P. Sekaly, and R. Cheynier Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection Blood, April 1, 2007; 109(7): 2912 - 2920. [Abstract] [Full Text] [PDF]

				P. Delobel, M.-T. Nugeyre, M. Cazabat, K. Sandres-Saune, C. Pasquier, L. Cuzin, B. Marchou, P. Massip, R. Cheynier, F. Barre-Sinoussi, et al. Naive T-cell depletion related to infection by x4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J. Virol., October 1, 2006; 80(20): 10229 - 10236. [Abstract] [Full Text] [PDF]

				M. Schechter and S. H. Tuboi Discordant immunological and virological responses to antiretroviral therapy J. Antimicrob. Chemother., September 1, 2006; 58(3): 506 - 510. [Abstract] [Full Text] [PDF]

				J. S. A. Stringer, I. Zulu, J. Levy, E. M. Stringer, A. Mwango, B. H. Chi, V. Mtonga, S. Reid, R. A. Cantrell, M. Bulterys, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA, August 16, 2006; 296(7): 782 - 793. [Abstract] [Full Text] [PDF]

				C. M. R. Kitchen, S. Philpott, H. Burger, B. Weiser, K. Anastos, and M. A. Suchard Evolution of Human Immunodeficiency Virus Type 1 Coreceptor Usage during Antiretroviral Therapy: a Bayesian Approach J. Virol., October 15, 2004; 78(20): 11296 - 11302. [Abstract] [Full Text] [PDF]

				E. Vergu, A. Mallet, and J.-L. Golmard Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection J. Antimicrob. Chemother., February 1, 2004; 53(2): 140 - 143. [Abstract] [Full Text] [PDF]

				J. D. Barbour, T. Wrin, R. M. Grant, J. N. Martin, M. R. Segal, C. J. Petropoulos, and S. G. Deeks Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults J. Virol., October 2, 2002; 76(21): 11104 - 11112. [Abstract] [Full Text] [PDF]

				M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF]

				L. P. Jacobson, R. Li, J. Phair, J. B. Margolick, C. R. Rinaldo, R. Detels, and A. Munoz Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression Am. J. Epidemiol., April 15, 2002; 155(8): 760 - 770. [Abstract] [Full Text] [PDF]

				R. S. Hogg, B. Yip, K. J. Chan, E. Wood, K. J. P. Craib, M. V. O'Shaughnessy, and J. S. G. Montaner Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy JAMA, November 28, 2001; 286(20): 2568 - 2577. [Abstract] [Full Text] [PDF]

				R. F. Kaltenbach III, G. Trainor, D. Getman, G. Harris, S. Garber, B. Cordova, L. Bacheler, S. Jeffrey, K. Logue, P. Cawood, et al. DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3021 - 3028. [Abstract] [Full Text] [PDF]

				W. Lu and J.-M. Andrieu In Vitro Human Immunodeficiency Virus Eradication by Autologous CD8+ T Cells Expanded with Inactivated-Virus-Pulsed Dendritic Cells J. Virol., October 1, 2001; 75(19): 8949 - 8956. [Abstract] [Full Text] [PDF]

				W. Lu, A. Achour, M. Arlie, L. Cao, and J.-M. Andrieu Enhanced Dendritic Cell-Driven Proliferation and Anti-HIV Activity of CD8+ T Cells by a New Phenothiazine Derivative, Aminoperazine J. Immunol., September 1, 2001; 167(5): 2929 - 2935. [Abstract] [Full Text] [PDF]

				T. Bohler, K.-M. Debatin, U. Wintergerst, W. Lu, and J.-M. Andrieu T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy Blood, March 15, 2001; 97(6): 1898 - 1901. [Full Text] [PDF]

				P. B. Gilbert, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes Virologic and Regimen Termination Surrogate End Points in AIDS Clinical Trials JAMA, February 14, 2001; 285(6): 777 - 784. [Abstract] [Full Text] [PDF]

				Immunologic and Virologic Responses Both Predict HIV Course Journal Watch (General), September 26, 2000; 2000(926): 2 - 2. [Full Text]

				R. M. Gulick Assessing the Benefits of Antiretroviral Therapy Ann Intern Med, September 19, 2000; 133(6): 471 - 473. [Full Text] [PDF]